A Trial Comparing the Efficacy of Insulin Degludec With Insulin Glargine on Glycaemic Control Using Continuous Glucose Monitoring in Patients With Type 1 Diabetes

Inclusion Criteria:

• Type 1 diabetes

• HbA1c (glycosylated haemoglobin) below or equal to 8.5%

• Current treatment with IGlar (insulin glargine) in a basal-bolus regimen with a totaldaily dose below 120 U

• BMI (body mass index) below 35 kg/m^2

Exclusion Criteria:

• Use within the last 3 months prior to visit 1 (screening) of any antidiabetic glucoselowering drug other than insulin/insulin analogues

• Subjects with regular use of acetaminophen who are not willing to use anotheranalgetic during CGM (Continuous Glucose Monitoring) periods

• Stroke; heart failure; myocardial infarction; unstable angina pectoris; coronaryarterial bypass graft or angioplasty within 24 weeks prior to visit 1

• Recurrent severe hypoglycemia (more than one severe hypoglycemic event during the last 12 months) or hypoglycemia unawareness or hospitalization for diabetic ketoacidosisduring the previous 6 months